Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...
The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.
Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...
AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback